BSE filing, NSE: SUVEN. Summary written from the filing by ALFA Finder's alert engine.
Suven Life Sciences Ltd: key numbers
- Share price
- ₹271.75
- Market cap
- ₹7,679 Cr
- Revenue (annual)
- ₹7.11 Cr
- Net profit (annual)
- ₹-276.3 Cr
- P/E (TTM)
- -21.8×Sector 52.8×
- Promoter holding
- 65.47%-4.61% QoQ
- FII holding
- 0.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Suven Life Sciences Ltd
All →Suven Life Sciences Board Meeting Date
Suven Life Sciences scheduled its board meeting for 5 November 2026 to approve Q1 and H1 FY27 unaudited results. The trading window closed from 1 October 2026 until 48 hours post-declaration.
Suven Life Sciences Other Announcement
Suven Life Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI regulations.
Suven Life Sciences Business Update
Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.
- clinical trial enrollment
- 424.0 patients
Suven Life Sciences Annual General Meeting
Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.
Suven Life Sciences Other Announcement
Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.
- Value
- ₹857.6 Cr
Suven Life Sciences Q1 FY27 Results: Net Loss of ₹127.6 Cr, Loss Widens
Suven Life Sciences Ltd reported revenue from operations of ₹3.6 Cr (+89.5% YoY) and a net loss of ₹127.6 Cr for Q1 FY27.
- Key figure
- Net loss ₹127.6 Cr
Other employee stock options announcements
All →Physicswallah Employee Stock Options
Physicswallah granted 1,84,828 ESOP 2025 options to eligible employees. Each option converts into one equity share at an exercise price of INR 1.
Manipal Payment and Identity Solutions Employee Stock Options
Manipal Payment sought postal ballot approval to amend, rename and ratify its ESOP 2024 scheme. Item three extends the scheme to group company employees.
RSWM Employee Stock Options
RSWM Limited instituted its 2026 ESOP scheme, granting 9,70,000 options at Rs.146 exercise price. Employees may exercise them after vesting, over up to four years.
- Execution
- Exercise over a maximum of 4 years from each vesting date; vesting over 1 to 4 years from grant
Viyash Scientific Employee Stock Options
Viyash Scientific allotted 228,408 shares under two employee stock option schemes. Paid-up capital rose to 44,19,91,958 shares of Rs.2 each.
Arvind Fashions Employee Stock Options
Arvind Fashions' board approved its AFL PSU Scheme 2026, covering up to 5,50,000 equity shares for employees. The scheme remains subject to shareholder approval.
Arvind SmartSpaces Employee Stock Options
Arvind SmartSpaces granted 10,000 stock options under its ESOP 2016 scheme at Rs. 563.85 exercise price. Options vest 2027-2030, with no cash value realised yet.
- Execution
- Vesting 01-11-2027 to 01-11-2030; exercisable within 5 years from vesting